Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Chondrogen

Cell therapy (Stem-cell derived) · developed by Mesoblast International Sàrl

Phase 1/2 Most advanced trial (none active)
MESO Developer
1 Registered trials

What is Chondrogen?

Chondrogen is a cell therapy made of ex vivo cultured adult human mesenchymal stem cells, given by intra-articular injection. It is studied for recovery following partial medial meniscectomy, a knee surgery.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Stem-cell derived)
Therapy area
Musculoskeletal
Developer
Mesoblast International Sàrl (MESO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00702741 Phase 1/2 Recovery Following Partial Medial Meniscectomy Completed MESO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Recovery Following Partial Medial Meniscectomy

More from Mesoblast International Sàrl

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.

Follow MESO, the company behind Chondrogen

See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MESO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.